Systemic Therapy with T-VEC in Advanced Melanoma
Keith Flaherty, MD; Jason Luke, MD, FACP; Rene Gonzalez, MD; and Jeffrey Weber, MD, PhD, describe the role for the melanoma immunotherapy talimogene laherparepvec (T-VEC) as a systemic therapy.
Keith Flaherty, MD; Jason Luke, MD, FACP; Rene Gonzalez, MD; and Jeffrey Weber, MD, PhD, describe the role for the melanoma immunotherapy talimogene laherparepvec (T-VEC) as a systemic therapy.